ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO916

Ionized and Total Magnesium Levels and Cardiovascular Risk in Patients with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Laville, Solene M., Centre Hospitalier Universitaire Amiens-Picardie, Amiens, Hauts-de-France, France
  • Pluquet, Maxime, Universite de Picardie Jules Verne, Amiens, Hauts-de-France, France
  • Mansencal, Nicolas, Ambroise Paré University Hospital, Cardiology department, Boulogne-Billancourt, Ile-De-France, France
  • Fouque, Denis, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes , France
  • Laville, Maurice, Universite Claude Bernard Lyon 1, Villeurbanne, Auvergne-Rhône-Alpes , France
  • Frimat, Luc, Centre Hospitalier Regional Universitaire de Nancy, Nancy, Grand Est, France
  • Massy, Ziad, Hopital Ambroise-Pare Service de Nephrologie Dialyse, Boulogne-Billancourt, Île-de-France, France
  • Kamel, Said, Universite de Picardie Jules Verne, Amiens, Hauts-de-France, France
  • Alencar de Pinho, Natalia, Centre de Recherche en Epidemiologie et Sante des Populations, Villejuif, Île-de-France, France
  • Liabeuf, Sophie, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, Hauts-de-France, France

We sought to determine whether serum ionized (iMg) and total (tMg) Mg levels are associated with major adverse cardiovascular events (MACE) in patients with CKD.


CKD-REIN is a prospective cohort of CKD outpatients (not on dialysis). Baseline iMg and tMg serum concentrations were respectively centrally measured using the NOVA BIOMEDICAL Stat Profile PRIME ES and with Atellica® CH SIEMENS analyzers. Adjusted cause-specific Cox proportional hazard models were used to estimate hazard ratios (HRs) for first MACE (CV death, myocardial infarction, stroke or hospitalization for heart failure).


Of the 2419 included patients (median [IQR] age: 68[60-76]; mean (SD) eGFR 33.5(13.5) mL/min/1.73 m2), 52% had a history of CV disease.
Correlation between iMg and tMg was very high (r=0.88; p<0.001).
Over a median follow-up of 4.4 years [IQR,2.3-5.0], 351 experienced a first MACE event, leading to an incidence rate [95%CI] of 3.9[3.5;4.3] per 100 person-years (figure).
After multiple adjustments, patients in Tertile 3 (T3) of iMg had a higher risk of MACE compared to patients in Tertile 1 (T1), HR [95% CI], 1.39[1.05;1.83]. No difference was noted for patients in Tertile 2 (T2) compared to patients in T1.
Regarding tMg, patients in T3 of total Mg had a higher risk of MACE compared to patients in T1 (HR=1.40[1.07;1.83]). A nonsignificant lower risk of MACE was noted for patients in T2 compared to patients in T1, revealing a potential U shape relation between MACE risk and tMg level.


This study suggests that high serum iMg and tMg levels are associated to cardiovascular outcomes in patients with moderate to advanced CKD. Further research is needed to explore the shape of the relationships and the mechanisms.


  • Government Support – Non-U.S.